EUVIMEDEUVIMED entdecken
Crossref

Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML

Matt Kalaycio

The Journal of Community and Supportive Oncology · 2013

DOI: 10.12788/j.cmonc.0046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Matt Kalaycio.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kalaycio, M. (2013). Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0046

Vancouver

Kalaycio M. Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0046

BibTeX
@article{Kalaycio2013,
  author = {Kalaycio, Matt},
  title = {Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML},
  journal = {The Journal of Community and Supportive Oncology},
  year = {2013},
  doi = {10.12788/j.cmonc.0046}
}
Kostenlos starten →